A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Global Dialysis Market to Reach $142.92 Billion by 2027

The “Dialysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.

The global dialysis market reached a value of US$ 104.13 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 142.92 Billion by 2027, exhibiting a CAGR of 5.42% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Dialysis Market Trends:

The growing number of diabetic and hypertension patients along with the increasing incidences of end-stage renal disease (ESRD) are primarily driving the global dialysis market. In line with this, the rising cases of chronic kidney disease (CKD), which has impelled patients to opt for hemodialysis to enhance their health while reducing the chances of developing nerve damage, are also propelling the market growth.

Furthermore, the shifting patient preferences from kidney transplantation towards dialysis to reduce health complications and improve quality care are positively influencing the global market. Besides this, the elevating inclination towards home dialysis, especially among the geriatric population suffering from chronic kidney dysfunctions, is acting as another growth-inducing factor.

Moreover, various initiatives undertaken by public healthcare organizations to spread awareness regarding the significance of maintaining kidney health and easy accessibility to multiple renal treatment options are further catalyzing the market growth. In line with this, the increasing government investments in upgrading healthcare infrastructures coupled with extensive R&D activities and clinical trials for treating CKD are also bolstering the global market.

Furthermore, the elevating prevalence of acute kidney injuries in COVID-19 infected patients is augmenting the demand for renal replacement therapy, including dialysis. Additionally, the introduction of sorbent-based regenerative technology that enables the delivery of high-dose dialysis with a low volume of dialysis solution while removing toxins is expected to drive the global dialysis market in the coming years.

Key Market Segmentation

Breakup by Type:

  • Hemodialysis
  • Conventional Hemodialysis
  • Short Daily Hemodialysis
  • Nocturnal Hemodialysis
  • Peritoneal Dialysis
  • Continuous Ambulatory Peritoneal Dialysis (CAPD)
  • Automated Peritoneal Dialysis (APD)

Breakup by Product and Services:

  • Services
  • Equipment
  • Dialysis Machines
  • Water Treatment Systems
  • Others
  • Consumables
  • Dialyzers
  • Catheters
  • Others
  • Dialysis Drugs

Breakup by End User:

  • In-center Dialysis
  • Home Dialysis

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Dialysis Market

6 Market Breakup by Type

7 Market Breakup by Product and Services

8 Market Breakup by End User

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

Companies Mentioned

  • Asahi Kasei Corporation
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton Dickinson and Company
  • DaVita Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • JMS Co. Ltd.
  • Medtronic plc
  • Nikkiso Co. Ltd.
  • NIPRO Corporation
  • Satellite Healthcare Inc.
  • Toray Industries Inc.

For more information about this report visit https://www.researchandmarkets.com/r/tpxyuf

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy